LEGALDIGMLEGALDIGM
    ← Code of Federal Regulations
    Beta
    21 CFR § 866.3946

    21 CFR § 866.3946 — § 866.3946 Dengue virus nucleic acid amplification test reagents.

    Beta. Legal information, not legal advice. LEGALDIGM is not a law firm. Check the official source for the current text.

    Analyze this law with AI
    § 866.3946 Dengue virus nucleic acid amplification test reagents. (a) Identification. Dengue virus nucleic acid amplification test reagents are devices that consist of primers, probes, enzymes, and controls for the amplification and detection of dengue virus serotypes 1, 2, 3, or 4 from viral ribonucleic acid (RNA) in human serum and plasma from individuals who have signs and symptoms consistent with dengue (mild or severe). The identification of dengue virus serotypes 1, 2, 3, or 4 in human serum and plasma (sodium citrate) collected from human patients with dengue provides epidemiologic information for surveillance of circulating dengue viruses. (b) Classification. Class II (special controls). The special control is FDA's guideline entitled “Class II Special Controls Guideline: Dengue Virus Nucleic Acid Amplification Test Reagents.” For availability of the guideline document, see § 866.1(e). [79 FR 53609, Sept. 10, 2014]

    Related guides, FAQ and contract templates